AGIOS PHARMACEUTICALS, INC. - AGIO
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G | Armistice Capital, LLC | 5.21% | 3,036,000 | View |
| Feb 17, 2026 | SCHEDULE 13G | Steven Boyd | 5.21% | 3,036,000 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital Partners, L.P. | 0.7% | 413,359 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners, L.P. | 0.8% | 446,450 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners II, L.P. | 0.2% | 136,781 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners III, L.P. | 0.1% | 56,489 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Four Crossings Institutional Partners V, L.P. | 0.2% | 97,883 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital Offshore Investors II, L.P. | 1.6% | 904,525 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital (AM) Investors, L.P. | 0.1% | 62,455 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Capital F5 Master I, L.P. | 0.2% | 113,104 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Healthcare Partners Master, L.P. | 5.0% | 2,928,459 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Partners, L.L.C. | 8.7% | 5,046,401 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Institutional (GP) V, L.L.C. | 0.2% | 97,883 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon F5 (GP), L.L.C. | 0.2% | 113,104 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Farallon Healthcare Partners (GP), L.L.C. | 5.0% | 2,928,459 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Dapice Joshua J. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Dreyfuss, Philip D. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Dunn Hannah E. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Fried, Richard B | 0.0% | 0 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Gehani, Varun N. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Giauque, Nicolas | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Husen, Avner A. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Kim, David T. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Linn, Michael G. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Luo Patrick (Cheng) | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Patel, Rajiv A. | 0.0% | 0 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Roberts, Jr., Thomas G. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Saito Edric C. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Seybold, William | 0.0% | 0 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Short Daniel S. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Spokes, Andrew J. M. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Warren, John R. | 8.8% | 5,159,505 | View |
| Feb 09, 2026 | SCHEDULE 13G/A | Wehrly, Mark C. | 8.8% | 5,159,505 | View |
| Dec 05, 2025 | SCHEDULE 13G/A | Bellevue Group AG | 0.0% | 0 | View |
| Dec 05, 2025 | SCHEDULE 13G/A | Bellevue Asset Management AG | 0.0% | 0 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital Advisors LP | 4.9% | 2,873,555 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital Advisors GP LLC | 4.9% | 2,873,555 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Senai Asefaw, M.D. | 4.9% | 2,873,555 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paradigm BioCapital International Fund Ltd. | 4.4% | 2,536,170 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.